<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83545">
  <stage>Registered</stage>
  <submitdate>28/01/2009</submitdate>
  <approvaldate>24/04/2009</approvaldate>
  <actrnumber>ACTRN12609000207213</actrnumber>
  <trial_identification>
    <studytitle>A randomised trial of Enbrel (Etanercept) administered epidurally for the treatment of lumbosacral pain (sciatica)</studytitle>
    <scientifictitle>A randomised, double-blind, placebo-controlled, phase 2a trial of ENBREL (Etanercept) administered by the transforaminal epidural route for the treatment of lumbosacral radiculopathy. (BDCISP2ENBREL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BDCISP2ENBREL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sciatic pain</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be assigned to 1 of 3 dose levels of Etanercept (0.5mg, 2.5mg or 12.5mg), which will be administered twice, 2 weeks apart via the epidural route.</interventions>
    <comparator>2mL of normal saline, administered twice, two weeks apart via the epidural route</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>to evaluate the safety of three different doses of Etanercept versus placebo when administered epidurally.  Safety will be assessed by the monitoring of adverse event information, physical examination, clinical laboratory tests and vital signs measurement.</outcome>
      <timepoint>From time of consent, safety will be assessed at each study visit and where necessary between study visits, until the final follow-up visit at Week 28.  There are 8 study visits scheduled over 28 weeks with Visit 1 (week -1), Visit 2 (Day 0), Visit 3 (Week 2), Visit 4 (Week 4), Visit 5 (Week 6), Visit 6 (Week 10), Visit 7 (Week 14), Visit 8 (Week 28).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the efficacy of three different doses of Etanercept versus placebo when administered epidurally for the treatment of lumbosacral pain by assessment of reduction in patient pain scores</outcome>
      <timepoint>From first dose to 6 months post dose, pain will be assessed by means of patient diary cards, completed for daily prior to the study visits. Study visits are completed at Visit 1 (week -1), Visit 2 (Day 0), Visit 3 (Week 2), Visit 4 (Week 4), Visit 5 (Week 6), Visit 6 (Week 10), Visit 7 (Week 14), Visit 8 (Week 28).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy males or females with primary diagnosis of sciatica (lumbosacral radiculopathy) of between 6 and 26 weeks duration.  Must have negative tuberculin skin test.  Sciatica must been confirmed by Magnetic Resonance Imaging (MRI), have positive straight leg raise at screening or positive femoral stretch test.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Body Mass Index (BMI)&gt;35kg.m2, documented history of allergic reaction to any of the study drugs, has clinically significant heart, lung, kidney or liver illness, has significant pain outside the area affected by the sciatica (radiculopathy), has had lumbar or sacral back surgery or plans for surgical intervention while in the study, has a documented history or Rheumatoid Arthritis or Inflammatory Arthritis, has had epidural corticosteroid injections in the back within 2 months of screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Centralised randomisation procedures to be used.</concealment>
    <sequence>Simple randomisation by using a randomisation table created using a computer program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Three doses of Etanercept will be assessed.  Patients will be randomised to the different dosing groups.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>2/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>5000</postcode>
    <postcode>6009</postcode>
    <postcode>3144</postcode>
    <postcode>6160</postcode>
    <postcode>3162</postcode>
    <postcode>2305</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bioassets Development Corporation</primarysponsorname>
    <primarysponsoraddress>888 Worcester Street, Suite 95
Wellesley MA 02482</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bioassets Development Corporation</fundingname>
      <fundingaddress>888 Worcester Street, Suite 95
Wellesley MA 02482</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>CMAX - a division of IDT Australia Limited</sponsorname>
      <sponsoraddress>274 Melbourne Street
North Adelaide SA 5006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to determine if administering Etanercept via the epidural route, will be more effective than placebo at reducing pain scores associated with lubosacral radiculopathy (Sciatica).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>North Terrace
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>23/12/2008</ethicapprovaldate>
      <hrec>081110</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cabrini Human Research Ethics Committee</ethicname>
      <ethicaddress>183 Wattletree Road, Malvern VIC 3144</ethicaddress>
      <ethicapprovaldate>31/03/2009</ethicapprovaldate>
      <hrec>07-02-03-09</hrec>
      <ethicsubmitdate>12/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Hospital Avenue, Nedlands WA 6009</ethicaddress>
      <ethicapprovaldate>14/05/2009</ethicapprovaldate>
      <hrec>2009-013</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Metropolitan Area Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>Fremantle Hospital
Alma Street, Fremantle WA</ethicaddress>
      <ethicapprovaldate>7/07/2009</ethicapprovaldate>
      <hrec>09/119</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>229 Greenhill Road, Dulwich, SA 5065</ethicaddress>
      <ethicapprovaldate />
      <hrec>B101/09</hrec>
      <ethicsubmitdate>1/07/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>John Hunter Hospital
Lookout Road
New Lambton, NSW</ethicaddress>
      <ethicapprovaldate>18/11/2009</ethicapprovaldate>
      <hrec>HREC/09/HNE/281</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Guy Ludbrook, Principal Investigator</name>
      <address>Department of Anaesthesia and Intensive Care,
Level 5, Eleanor Harrald Building
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 8222 5422</phone>
      <fax>+61 8 8222 5887</fax>
      <email>guy.ludbrook@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kate Beard</name>
      <address>CMAX
274 Melbourne St
North Adelaide SA 5006</address>
      <phone>+61 8 8416 3100</phone>
      <fax>+61 8 8361 8615</fax>
      <email>kate.beard@cmax.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kate Beard</name>
      <address>CMAX
274 Melbourne St,
North Adelaide SA 5000</address>
      <phone>+61 8 8416 3100</phone>
      <fax>+61 8 8361 8615</fax>
      <email>kate.beard@cmax.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>